Conditions: Breast Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 41
Healthy volunteers: no

Brief summary:
The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.

Detailed description:

Arms:
arm 1: BIBW 2992 (Afatinib) once daily until progression

Interventions: intervention 1: BIBW 2992
Intervention descriptions: intervention 1: None

Protocol document: